Pacad Investment Ltd. Boosts Stake in Spark Therapeutics, Inc. (ONCE)

Pacad Investment Ltd. raised its stake in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 75.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 3,500 shares of the biotechnology company’s stock after purchasing an additional 1,500 shares during the quarter. Pacad Investment Ltd.’s holdings in Spark Therapeutics were worth $209,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of ONCE. Teachers Advisors LLC increased its holdings in shares of Spark Therapeutics by 16.8% during the 4th quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock worth $1,691,000 after purchasing an additional 4,875 shares during the period. Nationwide Fund Advisors increased its holdings in shares of Spark Therapeutics by 2.5% during the 1st quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock worth $923,000 after purchasing an additional 414 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Spark Therapeutics by 131.8% during the 1st quarter. Wells Fargo & Company MN now owns 522,894 shares of the biotechnology company’s stock worth $27,891,000 after purchasing an additional 297,277 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Spark Therapeutics by 10.9% during the 1st quarter. Bank of New York Mellon Corp now owns 111,043 shares of the biotechnology company’s stock worth $5,923,000 after purchasing an additional 10,916 shares during the period. Finally, TD Asset Management Inc. increased its holdings in shares of Spark Therapeutics by 4.5% during the 1st quarter. TD Asset Management Inc. now owns 76,451 shares of the biotechnology company’s stock worth $4,078,000 after purchasing an additional 3,300 shares during the period. Institutional investors own 91.01% of the company’s stock.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 9,331 shares of Spark Therapeutics stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $65.00, for a total value of $606,515.00. Following the completion of the sale, the chief executive officer now owns 230,534 shares in the company, valued at approximately $14,984,710. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen W. Webster sold 2,337 shares of Spark Therapeutics stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $71.12, for a total transaction of $166,207.44. Following the completion of the sale, the chief financial officer now owns 4,837 shares of the company’s stock, valued at approximately $344,007.44. The disclosure for this sale can be found here. Insiders sold a total of 374,160 shares of company stock valued at $26,723,411 in the last quarter. Corporate insiders own 7.30% of the company’s stock.

Several research firms have recently issued reports on ONCE. BMO Capital Markets restated an “outperform” rating and set a $89.00 price objective (up previously from $69.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $60.00 to $100.00 in a report on Tuesday, August 8th. Cowen and Company restated an “outperform” rating and set a $95.00 price objective (up previously from $75.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, UBS AG restated a “buy” rating and set a $92.00 price objective (up previously from $70.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the stock. Spark Therapeutics has a consensus rating of “Buy” and an average target price of $83.77.

ILLEGAL ACTIVITY NOTICE: This report was posted by Stock Observer and is the property of of Stock Observer. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.thestockobserver.com/2017/09/13/pacad-investment-ltd-boosts-stake-in-spark-therapeutics-inc-once.html.

Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) opened at 82.34 on Wednesday. The company’s market cap is $2.57 billion. The company has a 50-day moving average of $83.07 and a 200-day moving average of $65.94. Spark Therapeutics, Inc. has a 1-year low of $35.07 and a 1-year high of $85.26.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the consensus estimate of ($1.75) by ($0.14). Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. During the same quarter last year, the firm earned ($1.04) EPS. Spark Therapeutics’s revenue for the quarter was up 14.7% compared to the same quarter last year. Equities analysts forecast that Spark Therapeutics, Inc. will post ($7.69) EPS for the current year.

Spark Therapeutics Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics, Inc. (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply